Drug intelligence / Profile preview

MEDI3617 + paclitaxel

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

MEDI3617 + paclitaxel is an investigational combination therapy for advanced solid tumors, specifically evaluated in clinical trials for cancers such as ovarian cancer. MEDI3617 is a fully humanized monoclonal IgG1 kappa antibody that selectively binds and inhibits angiopoietin-2 (Ang2), thereby blocking the interaction of Ang2 with its receptor Tie2, and inhibiting angiogenesis (the formation of new blood vessels). Paclitaxel is a well-known cytotoxic chemotherapy agent that stabilizes microtubules and inhibits cancer cell mitosis. The combination was explored because simultaneous angiogenesis inhibition and cytotoxic chemotherapy may enhance antitumor effects.

Targets

ANGPT2 (Angiopoietin-2)TUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on MEDI3617 + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDI3617 + paclitaxel.